Literature DB >> 9733755

Detailed comparison of two molecular models of the human CD40 ligand with an x-ray structure and critical assessment of model-based mutagenesis and residue mapping studies.

J Bajorath1.   

Abstract

The interactions between the B cell receptor CD40 and its ligand on T cells are critical for the integrity of immune responses. The human CD40 ligand gp39, a tumor necrosis factor-like protein, has been the subject of intense efforts to identify the receptor-binding site and to analyze naturally occurring mutations that compromise gp39 function in vivo. These investigations relied heavily on molecular models of gp39, built in the presence of only approximately 25% sequence identity to tumor necrosis factor. The x-ray structure of gp39 has made it possible to assess modeling accuracy and to evaluate the results of model-based mutagenesis analyses. Although the models display local errors, their accuracy was sufficient to predict the CD40-binding site, to map natural mutations, and to rationalize their effects. One of five gp39 residues critical for CD40 binding was displaced in the models, and 1 of 21 point mutants was incorrectly classified. Factors most important for the reliability of the molecular models and their successful applications were valid sequence alignments and the focus of experimental studies on regions of high prediction confidence. Analysis of mutagenesis experiments correlated with anti-gp39 monoclonal antibody binding studies to assess the conformational integrity of mutant proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733755     DOI: 10.1074/jbc.273.38.24603

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.

Authors:  Peter Ellmark; Camilla Ottosson; Carl A K Borrebaeck; Ann-Christin Malmborg Hager; Christina Furebring
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

2.  Functional interaction of CD154 protein with α5β1 integrin is totally independent from its binding to αIIbβ3 integrin and CD40 molecules.

Authors:  Youssef El Fakhry; Haydar Alturaihi; Daniel Yacoub; Lihui Liu; Wenyan Guo; Claire Leveillé; Daniel Jung; Lara Bou Khzam; Yahye Merhi; John A Wilkins; Hongmin Li; Walid Mourad
Journal:  J Biol Chem       Date:  2012-03-29       Impact factor: 5.157

3.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

4.  Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction.

Authors:  Emilio Margolles-Clark; Oliver Umland; Norma S Kenyon; Camillo Ricordi; Peter Buchwald
Journal:  J Mol Med (Berl)       Date:  2009-08-26       Impact factor: 4.599

Review 5.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

6.  Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface.

Authors:  J Bajorath
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

Review 7.  Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis.

Authors:  Ghada S Hassan; Suzanne Salti; Walid Mourad
Journal:  Cells       Date:  2022-05-25       Impact factor: 7.666

8.  A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

Authors:  Erin E Thacker; Masaharu Nakayama; Bruce F Smith; R Curtis Bird; Zhanat Muminova; Theresa V Strong; Laura Timares; Nikolay Korokhov; Ann Marie O'Neill; Tanja D de Gruijl; Joel N Glasgow; Kenzaburo Tani; David T Curiel
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

9.  Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome.

Authors:  E López-Granados; R Cambronero; A Ferreira; G Fontán; M C García-Rodríguez
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

10.  Residue-Specific Message Encoding in CD40-Ligand.

Authors:  Aditya Yashwant Sarode; Mukesh Kumar Jha; Shubhranshu Zutshi; Soumya Kanti Ghosh; Hima Mahor; Uddipan Sarma; Bhaskar Saha
Journal:  iScience       Date:  2020-08-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.